Pediatric immunization is an important factor in providing protection against numerous common preventable diseases. The success of the pharmaceutical industry in developing new pediatric vaccines has resulted in a crowded recommended immunization schedule requiring several clinic visits over the first 12 years of life. Operations research models have been developed and used to make economically sound procurement choices from among a growing number of competing vaccine products. One factor that has not been incorporated into such models is the economic impact of wastage on such decisions. This paper reports results obtained from a vaccine selection algorithm that incorporates vaccine wastage data. The lowest overall cost formularies comparing no wastage costs with wastage costs are presented. A sensitivity analysis of the vaccine formulary with respect to the wastage rates associated with each available vaccine is provided. The maximum permissible wastage rate for each vaccine is determined for which the vaccine earns a place in the lowest overall cost formulary. This research provides health maintenance organizations and healthcare providers information that can be used to gain a better understanding of wastage and its impact on pediatric formulary costs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2003.11.018 | DOI Listing |
Asian Pac J Cancer Prev
January 2025
Parul Institute of Applied Sciences, Parul University, Vadodara, India.
Background: Breast cancer remains a significant global health challenge, requiring innovative therapeutic strategies. In silico methods, which leverage computational tools, offer a promising pathway for vaccine development. These methods facilitate antigen identification, epitope prediction, immune response modelling, and vaccine optimization, accelerating the design process.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Experimental Therapy Department, Iraqi Center for Cancer and Medical Genetic Research. Mustansiriyah University, Baghdad, Iraq.
Background: The use of bacterial vaccines as a potential Bacterial-Based Cancer Therapy (BBCT) presents an innovative approach, transforming these vaccines into multifunctional tools capable of serving dual roles in medicine.
Materials And Methods: This study aimed to conduct in vitro, immunity-independent experiments to investigate the anticancer properties of vaccine-derived bacterial toxoids on various cancer cell lines. Six concentrations of the DTP vaccine (5 x 10-4, 25 x 10-5, 125 x 10-6, 625 x 10-7, 312 x 10-7, and 15 x 10-6 µg/ml) were tested on two cancer cell lines (SKG and HCAM) and a normal Rat Embryonic Fibroblast (REF) cell line.
Asian Pac J Cancer Prev
January 2025
Research Center for Vaccine and Drugs, The National Research and Innovation Agency (BRIN), South Tangerang 15310, Indonesia.
Objective: The progress made in cancer immunology has led to the development of innovative therapeutic strategies. However, despite these advances, the superficial characteristics of immune cells have been frequently overlooked: This oversight may be attributed to a limited understanding of the intricate relationships between immune cells and their microenvironment. This study seeks to address this limitation by comprehensively examining cell size and granularity in breast cancer (BC) patients and healthy donors (HD).
View Article and Find Full Text PDFDrug Saf
January 2025
Forum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.
HIV-prevention efforts focusing on women of child-bearing potential are needed to end the HIV epidemic in the African region. The use of antiretroviral drugs as pre-exposure prophylaxis (PrEP) is a critical HIV prevention tool. However, safety data on new antiretrovirals during pregnancy are often limited because pregnant people are excluded from drug development studies.
View Article and Find Full Text PDFMol Divers
January 2025
Center of Bioinformatics, College of Life Sciences, Northwest Agriculture and Forestry University, Yangling, 712100, Shaanxi, China.
Melanoma, a highly aggressive skin cancer, remains a significant cause of mortality despite advancements in therapeutic strategies. There is an urgent demand for developing vaccines that can elicit strong and comprehensive immune responses against this malignancy. Achieving this goal is crucial to enhance the efficacy of immunological defense mechanisms in combating this disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!